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ABBREVIATIONS 
cAMP cyclic adenosine 3’,5’-
monophosphate 
CD cluster of differentiation 
CpG cytosine-phosphate-guanosine 
DNA deoxyribonucleic acid 
ELISA enzyme-linked immunosorbent 
assay
EMD enamel matrix derivative 
ERK extracellular signal-related 
kinase 
G+/÷ Gram-positive/negative 
HDL high-density lipoprotein 
IL interleukin 
IRF interferon-regulatory factor  
LAMP lysosome associated membrane 
protein 
LBP lipopolysaccharide-binding 
protein 
LDL low-density lipoprotein 
LPS lipopolysaccharide 
LXR liver x receptor 
MAMP microbe-associated molecular 
pattern 
MAPK mitogen-activated protein 
kinase 
MCP monocyte chemoattractant 
protein 
MDP muramyl dipeptide 
MIP macrophage inflammatory 
protein 
MMP matrix metalloproteinase 
mRNA messenger ribonucleic acid 
MODS  multiple organ dysfunction 
syndrome  
MyD  myeloid differentiation protein 
NF nuclear factor 
NOD nucleotide-binding 
oligomerization domain 
PBMC peripheral blood mononuclear 
cells
PepG peptidoglycan 
PGLYRP peptidoglycan recognition 
protein 
PI3K phosphatidylinositol 3-kinase 
PMN polymorphonuclear cells 
PPAR peroxisome proliferator-
activated receptor 
PRR pattern recognition receptor 
RT-PCR reverse transcriptase 
polymerase chain reaction 
TGF tumor growth factor 
TLR toll-like receptor 
TNF tumor necrosis factor 
TRAM  TRIF-related adaptor molecule 
TRIF toll-interleukin-1 receptor-
related adaptor protein inducing 
interferon
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INTRODUCTION
Throughout the last couple of decades the scientific community has steadily warmed to 
the thought of the innate immune system as an appropriate object of study. Most 
immunologists have traditionally thought of innate immunity as a very crude and 
primitive host defense system, subordinate to the complexity, specificity and efficacy of 
the adaptive immune response. The discovery of toll-like receptors (TLRs) with inherited 
specificity for microbiological motifs, and the realisation that an efficient host response 
(innate and adaptive) is under the control of TLR signaling, have dramatically widened 
our understanding of infectious immunology and inflammatory disease. Most 
investigators now believe the two paradigms of immunity to be entwined and appreciate 
the intricate relationship between the two. This thesis is limited to attend to a few concepts 
of innate immunity and inflammation, most importantly the interactions of some 
conserved bacterial motifs with circulating human leukocytes, and ways in which the 
subsequent inflammation can be modulated. 
Endotoxins
Endotoxins are molecules closely associated with the cytoplasm or cell wall of certain 
micro-organism. They are biologically characterized by their ability to cause fever and in 
sufficient doses - shock and death. Another defining feature is that they induce 
inflammation through interaction with specific high-affinity receptors on leukocytes 
(reviewed in [1]).  Endotoxins have been the focus of extensive research for more than a 
century, and have for most of these years been synonymous with lipopolysaccharide 
(LPS) of Gram-negative (G÷) bacteria [1]. LPS is an important structural component of the 
outer leaflet of the outer membrane of G÷ bacteria (Figure 1), containing a polysaccharide 
and a lipid component, lipid A, which serves to anchor LPS in the bacterial cell wall and 
also accounts for the interactions of LPS with the host’s immune system.  
In recent years, other components of bacterial cell walls, most prominently 
lipoteichoic acid and peptidoglycan (PepG), have been recognized to have endotoxic 
properties (reviewed in [2]). PepG is an integral structural part of both G+ and G÷ bacterial 
cell walls (Figure 1); although it makes up a much larger part of G+s (the layer is 20-80 
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nm vs. 7-8 nm thick). PepG consists of a glycan backbone with alternating moieties of N-
acetylglucosamine acid and N-acetyl muramic acid, where the muramic acid acts as the 
linking substance between peptides and sugars. The peptide is composed of alternating L- 
and D-amino acids; the first is always L-alanine and the second and fourth are invariably 
D-glutamine and D-alanine. The PepG that makes up the thin layer in Gram-negative 
bacteria is characterized by a mesodiaminopimelic acid in the third position. Different 
types of cross-linkage between the peptides occur (Figure 2).
The emergence of alternative bacterial motifs has widened the scope of endotoxin 
research and is a natural consequence of the fact that the incidence of G+ sepsis is 
increasing, accounting for 33% of incidences in Norway in 1999 [3] and 52% in the 
United States in 2000 [4]. The prevalence pattern of nosocomial infections have changed 
the most, in part due to the outburst of methicillin-resistant Staphylococcus aureus strains.
Figure 1. Prototypical cell walls of G+ and G÷ bacteria. The peptidoglycan layer (blue) is thicker in 
G+ than in G÷ bacteria (20-80 nm vs. 7-8 nm). 
Bioavailability and interactions with the host
In order to elicit the pathophysiological changes of endotoxemia, endotoxins need to 
escape their embedment in the bacterial cell walls and interact with the host. During 
normal growth, LPS is continuously shed [5], and lipid A is subsequently exposed to the 
host environment, where it ignites signaling cascades which will be reviewed later on. 
PepG is also shed in significant amounts during bacterial growth, although this might be 
restricted to certain strains (reviewed in [6]). Both LPS and PepG are released from 
bacteria during an infection, as the consequence of bacterial lysis, and they can reach the 
circulation through translocation from the intestine, although it is uncertain whether this is 
mainly an indicator of bacterial translocation or direct absorption of endotoxins across the 
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intestinal wall [7;8]. In addition, some antibiotics (especially ȕ-lactams) potently enhance 
the release of endotoxins from both G+ and G÷ bacteria (reviewed in [9]), although this is 
of unknown clinical relevance.
Gram+ peptidoglycan
(S.aureus)
Gram÷ peptidoglycan
(E.coli)
Figure 2. Organization and structure of PepG. There are two main structural differences between G+
and G÷ PepG: Cross-linkage is more widespread in G+ PepG, and PepG from G÷ bacteria is
characterized by the mesodiaminopimelic acid in the third position of the stem peptide. D/L-Ala, D/L-
alanine; D-Glu, D-glutamine; Gly, Glycine, L-Lys, L-lysine; m-DAP, mesodiaminopimelic acid.
The cellular interactions of endotoxins with the host are mainly mediated by tissue 
macrophages and blood leukocytes. LPS and PepG are members of a broader class of 
conserved microbiological motifs, called microbe-associated molecular patterns 
(MAMPs), which activate the innate immune system. In contrast with other cell types
which are generally relatively indifferent to MAMPs, cells of the hematopoietic lineage 
express a host of pattern recognition receptors (PRRs) that recognize MAMPs and these 
are of primary importance for the in vivo response to LPS [10]. Increasing knowledge 
about PRRs has emerged in the last decade and has revolutionized the way we think of the 
innate immune system. Most notably the TLRs have been discovered to play instrumental
roles in integrated immunity by conferring responsiveness to a number of different 
bacterial motifs (reviewed in [11]), TLR4 being the cell-activating receptor for LPS [12]. 
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The nucleotide-binding oligomerization domains (NODs) are another class of MAMP 
receptors, binding muropeptides, the building blocks of PepG [13;14]. 
LPS engages in a complex with LPS-binding protein (LBP) which binds to the CD14 
receptor [15]. Subsequently, a signal is relayed across the cell membrane by TLR4, which 
requires the cell surface molecule MD-2 for activation [12;16]. TLR2 has for some time 
been believed to relay PepG signaling [17-20], but there is evidence that the intracellularly 
located NOD1 and NOD2 are the true cell activating receptors for PepG [13;14;21;22], 
through detection of its minimal bioactive substructures muramyl dipeptide (MDP, part of 
both G+ and G÷ PepG) and diaminopimelic acid-containing tripeptides (only in G÷ PepG). 
In addition cryoporin/NALP3 has been identified as yet another cell activating receptor 
for MDP [23;24], although other studies have not reached similar conclusions [25]. The 
PepG recognition proteins (PGRP, named PGLYRP in mammals) are a set of newly 
discovered pattern recognition receptors. They do not confer cell activation in mammals, 
but serve bactericidal functions, partaking in neutrophil killing of intra- and extracellular 
bacteria [26;27], and enzymatically digesting PepG molecules (Figure 3) [28]. 
Host response 
Engagement of TLR4 by LPS leads to recruitment of adaptor molecules (myeloid 
differentiation protein-88 [MyD88], Mal, toll-interleukin-1 receptor-related adaptor 
protein inducing interferon [TRIF] and TRIF-related adaptor molecule [TRAM]) to its 
intracellular domain. Two major inflammatory pathways - nuclear factor-țB (NFțB) [29] 
and interferon-regulatory factor 3 (IRF3) [30], are activated via MyD88/Mal and 
TRIF/TRAM, respectively (reviewed in [31]) (Figure 3). Whereas activation and nuclear 
translocation of NFțB leads to tumor necrosis factor (TNF)Į transcription, IRF3 
activation typically induces interferons implicated in anti-viral defense. The mitogen-
associated protein kinase (MAPK) family (ERK1/2, JNK, p38) also participate in 
signaling events downstream of TLR4 (reviewed in [32]). In total, activation of TLR4 
turns on more than 1.000 genes, of which 75% are MyD88-independent [33]. They 
include pro-inflammatory cytokines (e.g. interleukin [IL]-1, IL-6, IL-12, TNFĮ,
macrophage migration inhibitory factor, high-mobility group B-1), anti-inflammatory 
cytokines (e.g. tumor growth factor (TGF)ȕ, IL-10), interferons, colony-stimulating 
factors, chemokines (IL-8, monocyte chemoattractant proteins [MCP], macrophage 
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inflammatory proteins [MIP]), receptors (tissue factor, TLR4, NOD2), inducible nitric 
oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and others [10;34-37]. 
When NOD proteins are activated by PepG fragments they associate with RICK/RIP2 
[38] to activate downstream signaling pathways, most notably NFțB pathway and 
MAPKs (reviewed in [39]). In addition, PepG seems to activate caspase-1 through the 
cryopyrin/NALP3 inflammasome, thereby stimulating the processing and secretion of IL-
1ȕ and IL-18 [23;24]. In summary PepG induces a variety of functionally different 
cytokines in monocytic cells, of which the chemokines have been demonstrated to be 
particularly strongly induced [40]. Among these IL-8 (CXCL8) represents the prototypical 
chemokine, recruiting neutrophilic granulocytes to a site of inflammation and inducing 
release of lysosomal enzymes and reactive oxygen species from activated neutrophils [41] 
(reviewed in [42]). 
.
Figure 3. The cellular response to LPS and PepG. The complexity of intracellular signaling pathways 
is substantially simplified. 
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Both LPS and PepG have been shown to enhance the release of matrix metalloproteinases 
(MMPs) from whole blood and neutrophilic granulocytes [43;44] in vitro, as well as in 
vivo endotoxemia [43;45]. MMPs are enzymes which are primarily involved in 
degradation and remodelling of extracellular matrix. More recently they have been heavily 
implicated in innate immune responses, and especially MMP-9 is believed to be an 
important inflammatory mediator (reviewed in [46]). This notion is supported by the fact 
that MMP-9-null mice are protected against LPS-induced shock [47] and experimental 
models of arthritis [48], bullous pemphigoid [49], and autoimmune encephalomyelitis 
[50]. MMP-9 plays a significant part in host defense, partly by inactivating serine protease 
inhibitor Į1-proteinase [51], which is an inhibitor of neutrophil elastase, an important 
mediator in the defense against G÷ infections [52]. 
The traditional view of sepsis has been that of an uncontrolled inflammatory response, 
or as Lewis Thomas put it: “Our arsenals for fighting off bacteria are so powerful...that we 
are more in danger from them than the invaders.”[53]. In line with this is the notion that 
the morbidity of sepsis or endotoxemia is largely mediated by an unrestrained cytokine 
storm. The prototypic inflammatory cytokines IL-1 and TNFĮ are quickly released from 
monocytes/macrophages and induce the secretion of a host of other cytokines from 
different leukocyte populations, as well as prostaglandins, leukotriens, nitric oxide, 
reactive oxygen species and cell adhesion molecules (reviewed in [54]). This systemic 
inflammatory response is associated with circulatory hypoxia, disseminated intravascular 
coagulation, microcirculatory collapse and massive infiltration of phagocytes, which 
initiate adult respiratory distress syndrome, renal failure, myocardial depression and 
multiple organ dysfunction syndrome (MODS) (reviewed in [55]). Some investigators 
have suggested that MODS is caused by metabolic shutdown, mediated by cytokine- or 
hormone-mediated depression of mitochondrial function, and that this is an adaptive 
response to severe or prolonged cellular stress [56]. Others argue that uncorrected, 
persisting microcirculatory dysfunction is the driving force in the pathophysiology of 
sepsis, leading to hypoxia, cellular distress and organ failure (reviewed in [57]). However, 
partly because of improvements in intensive care, few patients die from circulatory 
collapse, hypoxemia or renal failure. They rather die because care is given up when 
prolonged treatment is considered futile [58]. 
The morbidity of sepsis may not solely be attributed to an excessive inflammatory 
response (reviewed in [58]). There is substantial evidence to suggest that most septic 
patients eventually become immunosuppressed, unable to eradicate the infectious agent 
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and predisposed to nosocomial infections [59] (reviewed in [60]). Potential mechanisms 
of immunosuppression are a shift from a Th1 to a Th2 response [61] (reviewed in [62]), T-
cell anergy [63], lymphocyte apoptosis [64;65] and inability of macrophages to activate T-
cells (reviewed in [58]). Endotoxin tolerance, the inability of leukocytes to respond to a 
second endotoxic challenge, is a well described phenomenon [66] (reviewed in [67]) It is 
associated with poorer clinical outcomes in ICU patients [68] and might be employed as a 
tool to identify and differentiate patients with sepsis from those with systemic 
inflammatory response syndrome [69;70].  
These phenomena may contribute to failure to clear a primary infection and a tendency 
to acquire secondary infections. The true picture is probably one that takes into account 
both the exaggerated inflammatory response and the compromised immune system. It 
must also be noted that septic patients are a highly heterogeneous group. While fulminant 
meningococcemia is characterized by a rapid progression of disease and high circulating 
levels of pro-inflammatory cytokines [71], an immunosuppressed patient contracting a 
nosocomial infection post-operatively is bound to be a different story. 
Metabolism in sepsis and the liver X receptor 
Sepsis is associated with a multitude of endocrine and metabolic alterations. It has been 
observed that patients admitted to intensive care units (ICUs) for both infectious and non-
infectious causes have markedly reduced values of both total cholesterol, low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL) [72]. Low cholesterol levels are 
strongly associated with exacerbation of disease and adverse outcome in several patient 
groups [73-75]. This may be due to the severity of the underlying disease (e.g. cancer, 
sepsis) which represents a catabolic driving force, but lipoproteins, especially HDL, are 
also known to interact with and neutralize LPS, and attenuate inflammation and MODS in 
experimental models [76;77]. Hyperglycemia and insulin resistance are common in 
critical illness, and not related to glucose homeostasis at baseline [78]. There is now 
substantial evidence to suggest that strict glucose control in the ICU significantly reduces 
morbidity and mortality [79;80]. 
The altered metabolism in critical illness and its potentially important role in the 
pathology of disease, has led investigators to target mechanisms governing lipid and 
glucose metabolism. The liver X receptor (LXR) belongs to the nuclear receptor 
superfamily (reviewed in [81]) and is a whole body master regulator of cholesterol 
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uptake, .transport and metabolism [82;83] and is also involved in the regulation of 
apoptosis and glucose sensitivity [84;85] (Figure 4). Its physiological ligands are 
oxysterols, oxidized metabolites of cholesterol, and in macrophages ligand binding 
initiates transcription of genes controlling reverse cholesterol transport, thereby 
protecting cells from lipid overload [86;87]. It has been demonstrated that LXR signaling 
has anti-inflammatory effects on rodent macrophages, suppressing LPS-induced genes 
including iNOS, COX-2, IL-1ȕ, IL-6, MCP, and MMP-9. In addition, LXR-null mice 
have enhanced cytokine responses to LPS challenge [88;89]. On this background our 
laboratory has recently introduced the concept that LXR may be a node in the 
pathophysiology of sepsis, and that impaired LXR signaling may, at least in part, underlie 
development of septic complications. We have demonstrated that pre-treatment with a 
synthetic LXR ligand protects against hepatic injury in a rat model of endotoxemia, by 
suppressing TNFĮ release from Kupffer cells [90], and that liver injury is aggravated in 
LXRĮ-deficient mice after cecal ligation and puncture, compared with wild type mice 
(unpublished results). A study in human monocytes, exploring the anti-inflammatory 
potential of LXR agonism is presented in the thesis (paper V)  
Figure 4. Cellular effects of LXR activation. Activation of LXR by its endogenous ligands, oxysterols, 
leads to dimerization with RXR and initiation of gene transcription. The results are promotion of 
cholesterol efflux and glucose sensitivity and inhibition of transcription of pro-atoptopic factors and 
release of pro-inflammatory mediators
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Enamel matrix derivative 
Enamel matrix derivative (EMD) is a substance extracted from developing porcine tooth 
buds. It primarily contains amelogenins, which are the major proteins of developing tooth 
enamel matrix and are predominantly involved in formation of enamel and dental 
cementum. There is substantial evidence that enamel matrix derivative (EMD) improves 
the clinical outcome of periodontal treatment in patients with severe periodontitis [91;92] 
and promotes healing of venous leg ulcers [93]. One observes an attenuation of gingival 
inflammation, enhancement of periodontal ligament and gingival fibroblast proliferation 
and promotion of vessel formation, thereby promoting healing of soft tissue wounds 
[92;94-97]. A local increase in the synthesis and secretion of growth factors and 
cytokines, including TGFȕ and IL-6, is involved [95], but the precise mechanisms of 
EMD-cell interactions are largely unknown. Lysosome associated membrane protein 
(LAMP)-1 and CD63 have recently been implicated in the recognition and internalization 
of amelogenins [98;99], but there are no reports of LAMP-1 or CD63 regulating signal 
transduction pathways.
The available literature suggests that EMD has immunomodulatory properties, but the 
potential effects of EMD on inflammatory responses, such as cytokine formation, remain 
mostly unexplored. However, it has been shown that cAMP is elevated in periodontal 
ligament and epithelial cells after exposure to EMD [95]. Factors that initiate intracellular 
formation of the second messenger cAMP down-regulate the monocyte/macrophage-
driven cytokine burst [100;101] and cAMP is known to inhibit activation of nuclear 
factor-țB and particularly the release of TNFĮ, as well as regulating several other 
mechanisms of innate and adaptive immunity [102;103] (reviewed in [104]).
In paper IV we aimed to elucidate the impact of EMD on endotoxin-induced 
inflammatory cytokine burst and whether this could be attributed to cAMP accumulation. 
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AIMS OF STUDY 
x To explore the structural requirements of PepG to interact with the innate immune 
system to induce cytokines in human blood and organ injury in rats. 
x To study the capacity of PepG to elicit the release of matrix metalloproteinase-9 and 
interleukin-8 and to alter the expression of NOD2 in human blood, monocytes and 
neutrophil granulocytes. 
x To explore the potential of amelogenin and an LXR agonist to modulate inflammation, 
assessed by the synthesis of pro- and anti-inflammatory cytokines, in human blood and 
monocytes.
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METHODS 
Whole blood model 
A whole blood model was used in papers I-V as developed and described previously by 
our laboratory [105]. Its main advantage is that it is a fast and easy way to explore 
inflammatory responses in a human cell system with complex leukocyte interactions. 
Venous blood is drawn from healthy volunteers, anticoagulated with heparin and 
incubated in plastic tubes at 37˚C with slow rotation. At different time points plasma is 
removed by centrifugation and frozen for later analyses. In other experiments CD14+ cells 
(monocytes, macrophages and a subset of granulocytes) are isolated using magnetic beads 
attached to a CD14 antibody (Dynabeads). RNA is thereafter isolated. 
 We have previously characterized this whole blood model [105] and have shown that 
pro-inflammatory cytokines (IL-1ȕ, IL-6, TNFĮ) are readily released into plasma upon 
exposure to LPS and that corresponding mRNA accumulates in CD14+ cells. Leukocyte 
viability is relatively stable (93,5 % at 24 h), pO2 decreases from 5.7 to 3.4 kPa in 24 h, 
while pCO2 is markedly increased, from 5.7 to 21 kPa. The rise in pCO2 is accompanied 
by a decrease in pH from 7.1 to 6.6. There is evidence that hypoxia can increase leukocyte 
responsiveness to LPS [106] and that cytokine release is augmented in macrophages 
exposed to high levels of CO2  [107;108]. We can therefore not exclude that altered gas 
tensions influence the inflammatory responses in this model. 
Primary cultures of human monocytes and neutrophilic granulocytes 
In papers II, III and V monocytes and neutrophils were isolated from venous blood drawn 
from healthy volunteers. The blood was subjected to density gradient centrifugation, 
according to principles described by Arne Bøyum [109].  In this procedure, blood is 
applied on top of a layer of Polymorphprep (AxisShield). Two distinct bands are formed 
by centrifugation, one containing polymorphonuclear cells (>95 % neutrophilic 
granulocytes, as determined by flow cytometry) and one containing mononuclear cells. To 
isolate monocytes from the mononuclear cell suspension, adherent monocytes are allowed 
to adhere to plastic plates, and lymphocytes and non-adherent cells are removed by 
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washing. By using this method we probably select a sub-population of blood monocytes, 
most likely those that are most differentiated towards macrophages. 
Quality control of PepG 
In endotoxin research the purity of bacterial products is of paramount importance. A 
number of important findings in the last couple of decades have to be interpreted with 
caution because it is difficult to exclude contamination or co-purification of the bacterial 
cell wall products with other bacterial components. Professor Simon J. Foster has 
provided us with highly purified PepG from S.aureus, Bacillus subtilis and 
Curtobacterium flaccumfaciens. PepG was purified as described for B.subtilis by 
professor Foster in 1992 [110]. In short, proteins were removed by pronase treatment and 
anionic polymers were removed from purified cell walls by treatment with hydrofluoric 
acid. The PepG was then washed numerous times and sterilized by autoclaving. It was 
subjected to gel electrophoresis with no evidence of protein, and the PepG was also 
enzymatically digested, obtaining the expected reverse-phase high-pressure liquid 
chromotography muropeptide profile with no spurious products. The PepG preparations 
were analysed for the presence of LPS by Limulus Amebocyte Lysate test, and was shown 
to contain 35 pg LPS per mg PepG. Moreover, pre-treatment with the LPS inhibitor 
polymyxin B or the CD14 antibody 18D11 (which specifically blocks LPS-induced 
signaling) had no effect on the production of TNFD induced by PepG [111]. Prior to 
experiments PepG was dispersed by sonication (3,000 Hz, 3 u 10 s).
In vivo endotoxemia 
In paper I, in vivo experiments were performed as described by Wang et al. [112]. First, 
male Wistar rats were anaesthetized with thiopentone sodium. Then, the trachea, right 
carotid artery and left jugular vein were cannulated to facilitate respiration, register mean 
arterial pressure and heart rate, and provide an access for administration of compounds. 
After surgery, heart rate and blood pressure were allowed to stabilize for 10–15 minutes, 
followed by slow injection of saline or PepG into the jugular vein over a 10-min period. 
The rectal temperature was kept at 37˚C throughout the experiment. The rats were 
euthanized at 6 h and plasma was collected for analyses of markers of hepatic 
injury/dysfunction (AST, ALT, ȖGT, bilirubin) and renal failure (urea, creatinine). 
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Assays
Enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), quantitative 
real-time reverse transcriptase polymerase chain reaction (qRT-PCR), and multiplex 
antibody bead analysis are standardized and commonly used methods of analysis and will 
not be described in further detail. Zymography was performed by Yun Yong Wang and 
Solveig Pettersen and I will therefore not elaborate on this method. Procedures are 
described in the methods section of each paper and are generally performed according to 
manufacturer’s instructions. 
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SUMMARY OF RESULTS 
Paper I 
In two models of PepG endotoxemia we showed that Staphylococcus aureus PepG 
induced markers of hepatic injury/dysfunction (AST, ALT, ȖGT, bilirubin) and renal 
failure (urea and creatinine) in the rat, and the release of functionally different cytokines 
(IL-6, IL-8, IL-10, and TNFĮ) in human blood. These effects were abrogated by 
enzymatically hydrolyzing the glycan backbone of PepG, but only weakly reduced by 
breaking the peptide cross-bridges, suggesting that the integrity of the glycan backbone of 
PepG is crucial for its endotoxic properties. However, the PepG fragments retained their 
ability to synergize with LPS. PepG from bacteria with different peptide side chains 
(S.aureus, C.flaccumfaciens, and B.subtilis) had similar immunostimulatory potentials. 
Paper II 
In this paper we demonstrated that S.aureus PepG induced the accumulation of MMP-9 in 
human blood. MMP-9 release was significantly enhanced in neutrophil cultures, and 
seemed to be the result of degranulation and not de novo synthesis, as the combined 
amount of intra- and extracellular MMP-9 was not increased by PepG. Inhibition of p38 
MAPK attenuated MMP-9 release, suggesting a role for p38 MAPK in neutrophil 
degranulation caused by PepG. 
Paper III
S.aureus PepG dose-dependently triggered prolonged release of IL-8 in primary cultures 
of human monocytes and neutrophilic granulocytes, as well as in whole blood. Inhibition 
of p38 MAPK and Src family kinases reduced IL-8 release in both cell types, whereas 
ERK1/2 and PI3K inhibition affected monocytes only. This suggests that differing 
signaling pathways are triggered by PepG in these cells. The basal level of NOD2 
expression was higher in monocytes than in neutrophils and was up-regulated by both 
PepG and LPS.
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Paper IV  
We revealed that enamel matrix derivative (EMD) containing amelogenins of different 
sizes attenuated the release of pro-inflammatory (TNFĮ, IL-8), but not anti-inflammatory 
(IL-10) cytokines in human blood challenged by endotoxins (PepG or LPS). The effect 
was most pronounced as pre-treatment. The anti-inflammatory effect of EMD was 
accompanied by cAMP accumulation in blood mononuclear cells, and as a cAMP 
analogue mimics the actions of EMD, we suggested that EMD’s anti-inflammatory 
potential can at least partly be attributed to increased intracellular cAMP. 
Paper V 
We showed that LXRĮ was up-regulated by LPS in human monocytes, suggesting a role 
for this receptor in inflammation. Furthermore, a synthetic LXR agonist attenuated the 
release of a multitude of cytokines (IL-1ȕ, IL-6, IL-8, IL-10, IL-12, TNFĮ, MIP-1Į/ȕ and 
MCP-1) induced by LPS, and to some extent PepG. This effect on cytokine release was 
neither accompanied by a down-regulation of endotoxin receptor expression, nor by 
attenuation of cytokine mRNA levels, suggesting that the LXR effect occurred via 
posttranscriptional mechanisms. 
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DISCUSSION 
This thesis aimed to explore the pathophysiology of endotoxemia from different points of 
view. First, from a microbiological point of view, with regard to the structure of PepG, 
secondly, from a cellular point of view, elucidating the cellular response to PepG, and 
ultimately from an interventionist point of view, modulating potentially important 
signaling events in order to re-establish homeostasis. 
 In Paper I we explored the biological activity of different PepG structures by cutting 
the molecule with two different enzymes. It has been known for some time that the 
integrity of the glycan backbone is of importance for PepG’s inflammatory potential [113-
115]. Our study was the first to report that PepG-induced organ injury in the endotoxemic 
rat is strongly attenuated by prior digestion of the glycan backbone. We also reported that 
cytokine formation and mRNA accumulation in an ex vivo whole human blood model 
were attenuated by loss of backbone integrity.
Human lysozyme digests glycan chains and is a major secretory molecule of both 
macrophages and neutrophilic granulocytes [116;117]. The importance of inactivating 
peptidoglycan is pin-pointed by the fact that lysozyme-deficient mice develop more severe 
inflammatory lesions after PepG exposure than their wild-type counterparts [118]. 
However, lysozyme-mediated bacterial killing might release large quantities of PepG into 
the bloodstream, augmenting the inflammation in sepsis and endotoxemia. There is also 
evidence that highly inflammatory substructures might be released upon degradation of 
PepG, approximating the potency of LPS [119]. 
This thesis highlights the fact that endotoxins cause the release of a multitude of 
functionally different cytokines and inflammatory mediators from human leukocytes. This 
is a well known feature of LPS, and we believe it is of great interest that also PepG 
induced the release of TNFĮ, IL-1ȕ, IL-6, IL-8, IL-10, IL-12, MIP-1Į, MIP-1ȕ, MCP-1 
and MMP-9 in our studies. In Paper II we focused on MMP-9, a matrix metalloproteinase 
involved in remodelling of extracellular matrix [46], and found that it is readily released 
from human neutrophils by degranulation in response to PepG. Degradation of tissue 
matrix might be beneficial in combating infections, making the site of infection more 
accessible for granulocytes and lymphocytes. In the context of sepsis and endotoxemia the 
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same properties of matrix metalloproteinases could be detrimental to the host, contributing 
to organ damage and circulatory collapse. Besides, MMP-9 has additional roles in 
inflammation, modulating the activity of pro-inflammatory cytokines (IL-1ȕ) [120] and 
chemokines (IL-8) [121]. In Paper III we focused on IL-8, which is a prototypical 
chemokine, mainly promoting attraction of neutrophils to a site of inflammation and 
subsequent release of lysosomal enzymes and respiratory oxygen species [42;122;123]. 
Serum levels of IL-8 correlate with severity of disease in sepsis patients [124;125] and is 
associated with the development of nosocomial pneumonia in multitrauma patients [126]. 
However, the significance of this remains uncertain, as high concentrations of IL-8 
actually may reduce recruitment of neutrophils and inhibit neutrophil-endothelium
interactions [127]. In summary, paper II and III provide further evidence in support of 
peptidoglycan as an important endotoxin. 
The two last studies included in this thesis explore ways of curbing the inflammatory 
potential of endotoxins. Paper IV aimed to elucidate the properties of a xenobiotic 
material, EMD, a substance mainly containing amelogenin proteins. Amelogenin has 
recently been shown to be expressed by a number of cell types, including cells of 
hematopoietic linage [128], implying that it might serve other functions than enamel and 
dental cementum formation. Basic and clinical research has demonstrated that EMD plays 
an important role in tissue regeneration [91-94], but although the literature suggests that 
EMD has immunomodulatory properties, this area is mostly unexplored. Our study is the 
first to demonstrate the effects of EMD on the inflammatory response of human blood 
leukocytes. We showed that EMD curbed the pro-inflammatory cytokine burst, but did not 
affect the anti-inflammatory response (IL-10), and that this pattern is almost similar to the 
effects of an increase in cAMP formation, which has been demonstrated to suppress TNFĮ
[129] and increase IL-10 [130]. EMD has been shown to enhance cAMP levels in 
periodontal ligament and epithelial cells [95], and cAMP accumulation was indeed 
induced by EMD in our study. Apart from this the cellular mechanisms behind the anti-
inflammatory effect are largely unknown. Some investigators have presented data 
demonstrating that amelogenin negatively regulates receptor activator of nuclear factor-țB
(RANK) ligand [131;132], which controls osteoclast formation and initiates a broad range 
of inflammatory cellular events in osteoclasts through RANK (reviewed in [133]). 
However, the cAMP/PKA pathway is known to enhance, rather than suppress, RANK 
ligand expression [134;135].
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EMD consists mainly of amelogenin, and when separated by gel electrophoresis a 
complex mixture of gene splice products are revealed [136]. These peptides have differing 
bioactivity [137], and it is unlikely that the whole protein (M180) is required to produce 
the observed effects. We have used recombinant amelogenin as well as smaller sequences 
in the whole blood model, without producing conclusive results, and this work should be 
taken further, not least because amelogenin fragments have differing solubility [138]. The 
hydrophobic properties became evident in a recent study from our lab, where EMD 
aggregated in capillary beds of pigs and caused a rise in systemic and pulmonary blood 
pressure [139]. There should be taken steps to isolate bioactive fragments which are 
applicable for systemic administration. 
In Paper V, we utilized a synthetic ligand to activate a well-known endogenous 
receptor, LXR. We found that the LXR agonist worked as a general suppressor of 
cytokine release in monocytes. When we went further to elucidate the cellular 
mechanisms, we were surprised to find that cytokine mRNA levels were not affected. 
Neither was there evidence of a diminished transport of mRNA out of the nucleus or a 
decreased cellular release. This is in line with studies we have done in rat Kupffer cells 
(unpublished results). Further work is underway to explore the underlying mechanisms of 
LXR’s effects, which could, according to preliminary data, involve mechanisms 
governing mRNA stability or translation, possibly thorough inhibition of p38 MAPK 
phosphorylation.
LXR is a whole body master regulator of reverse cholesterol metabolism, insulin 
sensitivity and apoptosis and partakes in several aspects of macrophage biology 
[81;82;84;88]. Low circulating levels of cholesterol [75], decreased glucose tolerance [79] 
and increased leukocyte apoptosis [64] are common in critically ill patients and predict a 
poor outcome. LXR potentially counteracts all these conditions, and hence, it is an 
extremely attractive molecule to target. We have previously demonstrated that an LXR 
ligand attenuates liver injury and Kupffer cell TNFĮ release in endotoxemic rats, and 
more recent work has shown that liver injury is aggravated in LXR deficient mice 
subjected to cecal ligation and puncture (unpublished results). Sepsis is a complex disease 
warranting complex approaches, and LXR has the potential to counteract sepsis at 
multiple levels. Therefore, studies are therefore underway to investigate the role and 
function of LXR in monocytes of septic patients. 
Merely placing a lid on endotoxin-induced pro-inflammatory mediator release is 
probably a too simplistic way of handling the pathophysiology of sepsis [140]. 
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Controlling excessive inflammation in the early phase of disease is certainly beneficial, 
but in the clinical setting one seldom gets the chance to apply a drug prior to the onset of 
controlled endotoxemia, and the measured cytokines might have come and gone and 
elicited late-onset responses (reviewed in [141]). In addition, cytokine formation is a 
crucial part of competent innate and adaptive immune responses [141], and abrogating 
them in the context of an out-of-control infection might be detrimental to the eradication 
of the infectious agent. Antibodies against TNFĮ or IL-1 have in several large phase III 
studies been ineffective and in some settings harmful, and anti-cytokine monotherapy is 
considered to be of limited value (reviewed in [142]). It is becoming increasingly clear 
that sepsis is an extensively complex process that affects various metabolic, endocrine, 
neurological and immunological factors [55;64;75;143]. What we preferably should try to 
do is restricting the excessive systemic inflammation, while at the same time addressing 
the whole picture with regard to metabolic dysfunction, apoptosis, immunological anergy 
and more. In this context, LXR agonism seems to provide an especially intriguing
possibility.
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